Clinical trial
Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell…
NCT00343356 · LanZhou University, Other · Completed
Key facts
| NCT number | NCT00343356 |
|---|---|
| Title | Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of Bladder |
| Official title | Clinical Study of Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of Bladder After Surgical Management |
| Lead sponsor | LanZhou University, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Bladder Neoplasms |
| Intervention type | Drug |
| Interventions | Trement |
| Enrollment | 138 |
| Start date | Jun 1, 1996 |
| Completion | Jul 1, 2003 |
| First posted | Jun 22, 2006 |
| Last update posted | Jun 22, 2006 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: